ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

Share this video  
Similar topics
Related videos
2:14
Key population-based registry studies in hematological oncology
Magnus Björkholm
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:30
LCL161 for primary myelofibrosis: a new therapy in the field
Naveen Pemmaraju
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
1:25
Highlights on myelofibrosis from ASH
Claire Harrison
Myeloproliferative Neoplasms
Ruxolitinib
ASCO 2015
Presentation
2nd June 2015
More from Jean-Jacques Kiladjian
Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
CONTI-PV: a 2-year follow-up of interferon product AOP2014
The 5-year update on the COMFORT-II clinical trial of ruxolitinib
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals